Aurobindo Pharma share price
You have to be logged in to add this to Watchlist.- ₹1,159.15(-2.98%)March 26, 2025 14:59:27 PM IST
- NSE
- BSE
- Vol : 562.52K (NSE + BSE)Last 20 day avg : 774.07 K
Aurobindo Pharma is trading -2.98% lower at Rs 1,159.15 as compared to its last closing price. Aurobindo Pharma has been trading in the price range of 1,205.95 & 1,155.50. Aurobindo Pharma has given -10.46% in this year & 5.10% in the last 5 days. Aurobindo Pharma has TTM P/E ratio 22.31 as compared to the sector P/E of 29.60.There are 25 analysts who have initiated coverage on Aurobindo Pharma. There are 10 analysts who have given it a strong buy rating & 9 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 845.81 Crores in its last quarter.Listed peers of Aurobindo Pharma include Aurobindo Pharma (-2.98%), Astrazeneca Pharma India (-0.24%), Pfizer (-1.97%).The Mutual Fund holding in Aurobindo Pharma was at 17.81% in 31 Dec 2024. The MF holding has decreased from the last quarter. The FII holding in Aurobindo Pharma was at 16.29% in 31 Dec 2024. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Mar 26, 2025, 09:29 AM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BLower than historical values2.35The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values19.98Price-to-earnings ratio based on trailing 12-month earnings
- BetaMedium volatility1.11Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.22The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 8.53% from Rs 7978.52 crore to Rs 7351.78 crore, year-on-year
The company's profit declined by 9.66% year-on-year during the December quarter, dropping from Rs 936.29 crore to Rs 845.81 crore- The debt to equity of the company is higher than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,181.78
- R2
- 1,305.62
- R3
- 1,381.18
- S1
- 982.38
- S2
- 906.82
- S3
- 782.98
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma | Neutral | 1,159.15 | -2.98 | 67,323.62 | 21.22 | 2.37 | 0.37 | 8.00 |
| Astrazeneca Pharma India | Bullish | 8,396.00 | -0.24 | 20,990.00 | 141.05 | 29.78 | 0.28 | 0.39 |
| Pfizer | Bearish | 4,008.55 | -1.97 | 18,338.21 | 34.23 | 5.21 | 0.85 | 1.51 |
| Neuland Laboratories | Bearish | 11,271.00 | -5.49 | 14,460.57 | 48.00 | 11.91 | 0.12 | 4.22 |
| Unichem Laboratories | Neutral | 680.00 | -2.04 | 4,787.59 | - | 2.1 | - | 2.64 |
- Pledged found - Promoter(s) have pledged 17.83% of shares.
- Promoter(s) have decreased pledged shares to 20.39% from 17.83% earlier.
- Promoter(s) holds a high stake in the company at 51.82%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.30 percentage points from previous quarter
- Mutual Funds holding has decreased by 0.72 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-06 | Quarterly Results |
| 2024-11-09 | Quarterly Results |
| 2024-08-10 | Quarterly Results |
| 2024-07-18 | Buy Back of Shares |
| 2024-05-25 | Audited Results |
- IndustryMajor Drugs
- ISININE406A01037
- BSE Code524804
- NSE CodeAUROPHARMA
Aurobindo Pharma is trading at 1159.15 as on Wed Mar 26 2025 09:29:27. This is -2.98% lower as compared to its previous closing price of 1194.75.
The market capitalization of Aurobindo Pharma is 67323.62 Cr as on Wed Mar 26 2025 09:29:27.
The average broker rating on Aurobindo Pharma is Buy. The breakup of analyst rating is given below -
- 10 analysts have given a strong buy rating
- 9 analysts have given a buy rating
- 2 analysts have given a hold rating
- 2 analysts have given a sell rating
- 2 analysts have given a strong sell rating
The 52 wk high for Aurobindo Pharma is 1592.55 whereas the 52 wk low is 995.00
Aurobindo Pharma can be analyzed on the following key metrics -
- TTM P/E: 22.31
- Sector P/E: 29.60
- Dividend Yield: 0.00%
- D/E ratio: -
Aurobindo Pharma reported a net profit of 3172.97 Cr in 2024.
The Mutual Fund Shareholding was 17.81% at the end of 31 Dec 2024.